Look beyond viral suppression to learn how people living with virologically suppressed HIV may still be candidates for antiretroviral therapy (ART) switch to improve treatment satisfaction and quality of life. Topics covered include:Reasons to consider regimen optimization in setting of viral suppressionAvailable switch regimens, including 2-drug regimens and long-acting ARTApproaches to assess for resistance before starting long-acting cabotegravir plus rilpivirine DHHS recommendations on proviral DNA genotypingART optimization strategies for patients living with viral suppression and history of underlying resistancePresenters:Brian R. Wood, MDProfessor of MedicineDivision of Allergy and Infectious DiseasesUniversity of WashingtonSeattle, WashingtonCristina Mussini, MDProfessor of Infectious DiseasesChief of the Division of Infectious Diseases, Policlinico, ModenaUniversity of Modena and Reggio EmiliaModena, Italy Link to full program and accompanying slides: https://bit.ly/4pAI66gGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related